<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02912247</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI303A201</org_study_id>
    <nct_id>NCT02912247</nct_id>
  </id_info>
  <brief_title>Comparative Clinical Trial to Evaluate Bioequivalency and Safety of Monoclonal Antibody Injection and Adalimumab in Chinese Healthy Volunteers</brief_title>
  <official_title>A Open, Randomized, Single-dose, Comparative Bioequivalency and Safety Study of Human Recombinant Anti-tumor Necrosis Factor Alpha Monoclonal Antibody Injection and Adalimumab in Chinese Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study is a phase 1 study which carried out to establish the pharmacokinetic&#xD;
      equivalence and equal safety of human recombinant anti-tumor necrosis factor alpha monoclonal&#xD;
      antibody injection and Adalimumab when used as a single subcutaneous injection in healthy&#xD;
      volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a comparative, open, randomized clinical study. The purpose of the study is to&#xD;
      demonstrate that human recombinant anti-tumor necrosis factor alpha monoclonal antibody&#xD;
      injection is equivalent to adalimumab in terms of pharmacokinetics and safety after single&#xD;
      subcutaneous injection in Chinese healthy volunteers.The study will enroll 180 healthy&#xD;
      volunteers, who will be randomized into 2 groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 27, 2016</start_date>
  <completion_date type="Actual">September 22, 2017</completion_date>
  <primary_completion_date type="Actual">September 22, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero to the last quantifiable concentration(AUClast)</measure>
    <time_frame>71days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero to infinity(AUCinf)</measure>
    <time_frame>71days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum serum concentration(Cmax)</measure>
    <time_frame>71days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to reach the maximum concentration(Tmax)</measure>
    <time_frame>71days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination rate constant(γz)</measure>
    <time_frame>71days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-live(T1/2)</measure>
    <time_frame>71days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance(CL/F)</measure>
    <time_frame>71days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution(V/F)</measure>
    <time_frame>71days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">183</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>monoclonal antibody injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection 40mg administered subcutaneously once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>adalimumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>adalimumab 40mg administered subcutaneously once</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection</intervention_name>
    <description>human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection, 40mg,subcutaneous injection,once</description>
    <arm_group_label>monoclonal antibody injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adalimumab</intervention_name>
    <description>adalimumab, 40mg,subcutaneous injection,once</description>
    <arm_group_label>adalimumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male, age between 18 and 55;&#xD;
&#xD;
          2. Body weight≥50kg and body mass index(BMI) within the range 19 to 28 kg/m2;&#xD;
&#xD;
          3. To fully understanding the purpose of the study, to understand the pharmacological&#xD;
             action of the study drugs and the possible adverse reactions; participants who are&#xD;
             voluntary to sign the informed consent according to the Declaration of Helsinki.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of adalimumab treatment;&#xD;
&#xD;
          2. History of relevant allergy/hypersensitivity(including allergy to the study drug or&#xD;
             its ingredient );&#xD;
&#xD;
          3. Participation in another interventional trial within 3 months prior to administration&#xD;
             of the study drug;&#xD;
&#xD;
          4. Blood donation(more than 200 mL within 12 weeks prior to administration of the study&#xD;
             drug);&#xD;
&#xD;
          5. Use of any drugs(including traditional Chinese medicine) within 2 weeks or at least 5&#xD;
             half-lives(whichever is longer) prior to administration;&#xD;
&#xD;
          6. History of cluster of differentiation 4 antagonist or tumor necrosis factor alpha&#xD;
             antagonist use, or use tumor necrosis factor antagonist(such as thalidomide) 3 months&#xD;
             prior to administration;&#xD;
&#xD;
          7. Abnormal significant clinically chest radiograph, ECG, or laboratory examinations at&#xD;
             screening and Baseline, judged by the investigators;&#xD;
&#xD;
          8. History of opportunistic infection(s)(such as: herpes zoster, mycoplasma, Pneumocystis&#xD;
             carinii, histoplasma, Aspergillus, mycobacterium) within 6 months prior to screening;&#xD;
&#xD;
          9. Known recurrent or chronic infectious disease(s) history, including but not limited&#xD;
             to: chronic kidney infect, chronic chest infection(such as bronchiectasis),&#xD;
             nasosinusitis, recurrent urinary tract infection, open, drainage or infected wounds of&#xD;
             the skin;&#xD;
&#xD;
         10. Tuberculosis(TB) history, or suspected clinically TB(including but not limited to:&#xD;
             pulmonary tuberculosis, lymphoid tuberculosis, tuberculous pleurisy), or a positive&#xD;
             Tuberculosis spot test;&#xD;
&#xD;
         11. Positive serology for human immunodeficiency virus(HIV) antibody;&#xD;
&#xD;
         12. Positive serology for hepatitis C virus antibody;&#xD;
&#xD;
         13. Active or chronic hepatitis B virus infection, such as positive hepatitis B virus&#xD;
             surface antigen;&#xD;
&#xD;
         14. History of organ transplant(except for corneal transplantation≥3 months prior to&#xD;
             Screening);&#xD;
&#xD;
         15. Known immunodeficiency history;&#xD;
&#xD;
         16. Use a live vaccine within 3 months prior to administration;&#xD;
&#xD;
         17. Alcohol or drug abuse within 12 months prior to Screening; unwilling/inability to&#xD;
             refrain from alcohol from 72 hours prior to administration and until during the trial&#xD;
             period;&#xD;
&#xD;
         18. Unwilling to use adequate contraception(such as condoms) during the study period;&#xD;
&#xD;
         19. Evidence suggests presence of clinically significant hepatic, renal, gastrointestinal,&#xD;
             cardiovascular, endocrine, respiratory, hematologic, or neurologic abnormality;&#xD;
&#xD;
         20. Mentally impaired;&#xD;
&#xD;
         21. Disabilities, bed rest, wheelchair dependent, or lack of activity of daily life;&#xD;
&#xD;
         22. Subjects who are unsuited to the study for any reason, judged by the investigators.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bei Hu, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>September 21, 2016</study_first_submitted>
  <study_first_submitted_qc>September 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2016</study_first_posted>
  <last_update_submitted>March 6, 2019</last_update_submitted>
  <last_update_submitted_qc>March 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tumor necrosis factor-a blocker</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Necrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

